Herb Cross

Form D signer

Herb Cross

Chief Financial Officer at Jasper Therapeutics

Form D signer

Capital raised by Jasper Therapeutics

$132.0M+$132.0M latest round

1 Form D filing · first filed Jul 2026 · Redwood City, CA

CURRENT ROLE: Chief Financial Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: —
30D INTEREST: 2 ↗

Career

1 company on file

Jasper TherapeuticsBiotech · Redwood City, CAsince Jul 2026

Chief Financial Officer

Signatory on Jasper Therapeutics's Form D filings · $132.0M raised across 1

Company filings

via EDGAR · Form D for Jasper Therapeutics1

DateCompanyFormAmountRole on filing

Jul 21, 2026Jasper TherapeuticsForm D+$132.0MChief Financial Officer

Form DJul 21, 2026 · Jasper Therapeutics+$132.0Mas Chief Financial Officer

Overview

Last filing Jul 21, 2026

Herb Cross is on file as Chief Financial Officer at Jasper Therapeutics in Redwood City, CA. Jasper Therapeutics has 1 Form D filing on record, $132.0M raised in total. Herb Cross appears as a signatory on the company's filings.

LinkedIn profile

Teammates

Jasper Therapeutics · 1

Matthew RosDirector

Products

Jasper Therapeutics · 1

BriquilimabMonoclonal antibody therapeutic

An investigational aglycosylated monoclonal antibody targeting KIT (CD117) that blocks stem cell factor signaling and depletes mast cells and hematopoietic stem cells via apoptosis, in development for chronic urticaria and progressing toward a pre-BLA meeting in severe combined immunodeficiency (SCID).